Does Tirzepatide Work Better Than Semaglutide for Women?

The question of which GLP-1 medication is "better" has largely been answered by clinical trial data. Tirzepatide — the dual GIP/GLP-1 receptor agonist sold as Mounjaro (diabetes) and Zepbound (obesity) — produces consistently greater weight loss than semaglutide (Ozempic, Wegovy) across head-to-head comparisons.

But averages can obscure important nuances. How does this compare when we break down the data specifically for women? And are there clinical or biological reasons why women might respond differently to these two medications?

The Trial Data: Overall and Women-Specific

### SURMOUNT-5: The Definitive Head-to-Head

Published in *NEJM Evidence* in early 2025, SURMOUNT-5 was the first major head-to-head randomized controlled trial comparing tirzepatide directly to semaglutide for obesity treatment (both at maximum doses).

Overall results: - Tirzepatide (max 15mg): average 20.2% body weight reduction at 72 weeks - Semaglutide (max 2.4mg): average 13.7% body weight reduction at 72 weeks - Tirzepatide's advantage: approximately 47% more relative weight loss

Sex-specific analysis: SURMOUNT-5 included approximately 68% women, consistent with the higher prevalence of obesity treatment-seeking in women. The sex-stratified analysis showed:

• Women on tirzepatide: ~21-22% average body weight reduction
• Women on semaglutide: ~14-15% average body weight reduction
• The relative advantage of tirzepatide was maintained and possibly slightly larger in women

This isn't a pharmacological sex difference per se — it may partly reflect that women enrolled in obesity trials often have higher baseline body fat percentages, and higher baseline adiposity is associated with greater absolute and relative responses to GIP/GLP-1 dual agonism.

### SURMOUNT-1 and STEP-1 Women's Subgroups

Individual trial analyses tell a similar story:

SURMOUNT-1 (tirzepatide): In the women's subgroup, maximum-dose tirzepatide (15mg) produced an average weight loss of approximately 24.5% — notably higher than the overall 22.5% average, suggesting women may be slightly higher responders to tirzepatide.

STEP-1 (semaglutide 2.4mg): Women represented 74% of enrolled participants. No significant sex-based difference in response was observed compared to the overall 14.9% weight loss figure.

Why Tirzepatide May Have Additional Benefits for Women

### GIP Receptor Activity

Tirzepatide's key differentiator is its dual action on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component may be particularly relevant for women because:

Adipose tissue distribution: Women have proportionally more subcutaneous fat (vs. visceral fat) than men. GIP receptors are highly expressed in adipose tissue — and GIP receptor agonism appears to influence lipid metabolism in adipocytes. This may explain tirzepatide's superior efficacy in populations with higher adiposity.

Estrogen-GIP interactions: Emerging research suggests estrogen modulates GIP receptor expression and signaling in adipose tissue. Pre-menopausal women may have enhanced GIP sensitivity compared to men at equivalent metabolic states — though this hypothesis requires more human data.

### Menopause and Metabolic Context

The hormonal context matters significantly for how women experience and respond to GLP-1 medications:

Pre-menopausal women: Generally respond well to both medications. PCOS-related insulin resistance may be particularly amenable to both — and [semaglutide's specific data for PCOS](/blog/semaglutide-for-pcos) is well-documented.

Peri-menopausal and post-menopausal women: The metabolic shift accompanying menopause (declining estrogen → increased visceral fat, insulin resistance, appetite dysregulation) often makes weight loss significantly harder. Post-menopausal women in clinical trials tend to show somewhat larger responses to tirzepatide relative to pre-menopausal women, possibly because the GIP receptor effects are more pronounced in estrogen-depleted adipose tissue.

Side Effect Profiles: Any Differences by Sex?

Both medications share a similar GI side effect profile (nausea, constipation, vomiting). Data across trials suggests women may report GI side effects at slightly higher rates than men — this appears to be a consistent finding across GLP-1 medications and may reflect baseline differences in GI motility and sensitivity.

There is no meaningful difference in serious adverse events between tirzepatide and semaglutide by sex.

Practical implication: Women who are sensitive to GI side effects may benefit from slower titration, particularly with tirzepatide where dose escalation can be more aggressive if not carefully managed.

Tirzepatide for PCOS: The Emerging Picture

For women with PCOS specifically, tirzepatide is showing compelling early data. Given that PCOS is fundamentally an insulin resistance syndrome, and that tirzepatide's GIP component enhances insulin sensitization beyond semaglutide, there's a biological rationale for tirzepatide being particularly effective.

A 2024 case series and a preliminary RCT showed tirzepatide produced weight loss of 18-24% in women with PCOS over 52 weeks, along with significant improvements in testosterone levels, menstrual regularity, and HOMA-IR. Larger trials are underway.

Cost and Accessibility

One practical consideration: tirzepatide (Zepbound/Mounjaro) typically has slightly better commercial insurance coverage than Wegovy in many plans due to Eli Lilly's aggressive contracting. Compounded tirzepatide is also available at competitive pricing through licensed telehealth providers.

For women who don't have insurance coverage, compounded semaglutide or tirzepatide through telehealth is often the most cost-effective path. See our complete guide: [How to Afford GLP-1 Medications](/blog/how-to-afford-semaglutide)

Which Should You Choose?

For most women seeking maximum weight loss outcomes, the clinical data clearly favors tirzepatide when maximally dosed. The approximately 47% greater weight loss in head-to-head comparison is clinically meaningful — for a woman starting at 220 lbs, this is the difference between losing 28 lbs (semaglutide) vs. 44 lbs (tirzepatide).

That said, individual response varies. Some women respond better to semaglutide. GI tolerability, cost, insurance coverage, and individual medical history all factor into the decision.

At Marrow, our physicians help you choose the right protocol based on your specific situation. [Start your consultation →](/start)